Ketorolac

From WikiAnesthesia
Revision as of 23:13, 23 February 2024 by Chris Rishel (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Ketorolac
Trade names

Toradol

Clinical data
Drug class

NSAID

Uses

Post-op pain

Contraindications

Renal disease or injury, peptic ulcer disease, GI bleeding

Routes of administration

IV, IM, oral

Dosage

IV or IM: 30mg once, if needed can repeat q6h up to 120mg daily

Dosage
Adult dosing
  • 10-30 mg IV
  • 0.33-1 mL of 30 mg/mL
Indication 
Analgesia
Route 
Intravenous
Preparation 

A 10 mg dose of ketorolac is as effective for acute pain control as a 15 or 30 mg dose1

  1. Motov S, Yasavolian M, Likourezos A, Pushkar I, Hossain R, Drapkin J, Cohen V, Filk N, Smith A, Huang F, Rockoff B, Homel P, Fromm C. Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2017 Aug;70(2):177-184. doi: 10.1016/j.annemergmed.2016.10.014. Epub 2016 Dec 16. PMID: 27993418.
Pharmacodynamics
Mechanism of action

Inhibition of COX (COX-1 > COX-2)

Pharmacokinetics
Onset of action

10-15 minutes

Duration of action

2-4 hours

Physical and chemical data
Article quality
Editor rating
In development
User likes
0

Ketorolac is a Non-Steroidal Anti-Inflammatory Drug (NSAID) that is frequently used intra-op for management of post-op pain.

Uses

  • Post-op pain management

Contraindications

Absolute contraindications

  • GFR < 30mL/min

Precautions

  • Chronic renal disease
  • AKI
  • GI bleeding
  • Peptic ulcer disease

Pharmacology

Pharmacodynamics

Mechanism of action

  • NSAID that inhibits COX
  • Of the NSAIDs, most selective for COX-1 inhibition over COX-2

Adverse effects

  • COX-1 selectivity increases risk for GI tract irritation and bleeding
  • Thromboembolic disease is always a consideration when using NSAIDs, although ketorolac has lower risk for exacerbating thromboembolic disease compared to more COX-2 selective agents like celecoxib

Pharmacokinetics

  • Highly protein bound
  • Almost completely renally eliminated

Chemistry and formulation

History

References

[1][2][3][4][5][6][7]

  1. Toda C, Naguib M. Peripherally acting analgesics. In: Flood P, Rathmell JP, and Urman RD (eds). Stoelting’s Pharmacology & Physiology in Anesthetic Practice. Sixth edition. Philadelphia, Pennsylvania; Wolters Kluwer; 2022: 257-65.
  2. "Nonsteroidal Anti-inflammatory Drugs".
  3. Colvin L. Physiology and pharmacology of pain. In: Thompson, JP, Moppett IK, and Wiles M (eds). Smith and Aitkenhead’s Textbook of Anaesthesia. 7th ed. Edinburgh; Elsevier; 2019: 99-120.
  4. Aronson JK. Non-steroidal anti-inflammatory drugs. In: Aronson, JK. Meyler’s Side Effects of Drugs: the International Encyclopedia of Adverse Drug Reactions and Interactions. Sixteenth edition. Amsterdam, Netherlands; Elsevier; 2016: 236-72.
  5. Hurley R, Elkassabany NM, Wu CL. Acute postoperative pain. In: Miller’s Anesthesia. 9th ed. Philadelphia; Elsevier; 2020:2620-22.
  6. Mahmoodi, Ahmad N.; Kim, Peggy Y. (2024), "Ketorolac", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31424756, retrieved 2024-02-14
  7. Buckley, Micaela M.-T.; Brogden, Rex N. (1990-01-01). "Ketorolac". Drugs. 39 (1): 86–109. doi:10.2165/00003495-199039010-00008. ISSN 1179-1950.